Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).

Caroline Robert(Centre National de la Recherche Scientifique), Alexander Christopher Jonathan Van Akkooi(Melanoma Institute Australia), Mario Mandalà(University of Perugia), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Xavier Durando(Inserm), Felix Boakye Oppong(European Organisation for Research and Treatment of Cancer), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Caroline Gaudy‐Marqueste(Aix-Marseille Université), Émilie Routier(Université Paris-Saclay), Anne-Sophie Govaerts(European Organisation for Research and Treatment of Cancer), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Emanuel Bührer(European Organisation for Research and Treatment of Cancer), Paul Lorigan(University of Manchester), Michelangelo Russillo(National Cancer Institute), Barouyr Baroudjian, Jean‐Luc Perrot(Centre Hospitalier Universitaire de Saint-Étienne), Bastian Schilling(Universitätsklinikum Würzburg), Eve‐Marie Neidhardt(Centre Léon Bérard), Ana Arance(Hospital Clínic de Barcelona)

Journal of Clinical Oncology

June 10, 2024

Cited by 8

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2014|2k

|New England Journal of Medicine|2018|1.8k

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).